Advances and new perspectives in the treatment of metastatic colon cancer  

作　　者：Gonzalo Recondo Jr Enrique Díaz-Cantón Máximo de la Vega Martin Greco Gonzalo Recondo Sr Matias E Valsecchi 

机构地区：[1]Department of Medical Oncology, Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Buenos Aires 1431, Argentina [2]Fundaleu, Fundación para combatir la Leucemia, Servicio de Oncología Clínica, Buenos Aires 1114, Argentina [3]Depatment of Medical Oncology, Hunting-ton Internal Medicine Group, Huntington, WV 25705, United States

出　　处：《World Journal of Gastrointestinal Oncology》2014年第7期211-224,共14页世界胃肠肿瘤学杂志（英文版）（电子版）

摘　　要：During the last decade we have witnessed an unprec-edented outburst of new treatment approaches for the management of metastatic colon cancer.Anti-angio-genic drugs,epidermal growth factor receptor blockers and multi-kinase inhibitors have all resulted in small but consistent improvement in clinical outcomes.However,this progress has paradoxically leaded us into new chal-lenges.In many cases the clinical development was done in parallel and the lack of head-to-head compari-son evolved into circumstances where several valid new"standards of care"are available.Even though desir-able in essence,the availability of many options as well as different possible combinations frequently leaves the busy clinician in the difficult situation of having to choose between one or the other,sometimes without solid evidence to support each decision.In addition,progress never stops and new agents are continuously tested.For these reason this review will try to summa-rize all the clinical trials that constitute the theoretical framework that support our daily practice but will also procure the reader with rational answers to common clinical dilemmas by critically appraising the current literature.Lastly,we will provide with a compilation of promising new agents that may soon become our next line of defense against this deadly disease.During the last decade we have witnessed an unprec-edented outburst of new treatment approaches for the management of metastatic colon cancer.Anti-angio-genic drugs,epidermal growth factor receptor blockers and multi-kinase inhibitors have all resulted in small but consistent improvement in clinical outcomes.However,this progress has paradoxically leaded us into new chal-lenges.In many cases the clinical development was done in parallel and the lack of head-to-head compari-son evolved into circumstances where several valid new'standards of care'are available.Even though desir-able in essence,the availability of many options as well as different possible combinations frequently leaves the busy clinician in the difficult situation of having to choose between one or the other,sometimes without solid evidence to support each decision.In addition,progress never stops and new agents are continuously tested.For these reason this review will try to summa-rize all the clinical trials that constitute the theoretical framework that support our daily practice but will also procure the reader with rational answers to common clinical dilemmas by critically appraising the current literature.Lastly,we will provide with a compilation of promising new agents that may soon become our next line of defense against this deadly disease.

关 键 词：Colon Cancer Stage Ⅳ Metastatic Review BEVACIZUMAB CETUXIMAB PANITUMUMAB AFLIBERCEPT REGORAFENIB 

分 类 号：R735.35[医药卫生—肿瘤]